ArticleScientific reports2020
Streptococcus gallolyticus abrogates anti-carcinogenic properties of tannic acid on low-passage colorectal carcinomas.
Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 29 citations in OpenAlex.
- Targeting the human gut microbiome: a comparative review of probiotics, prebiotics, synbiotics, and postbiotics.Journal of advanced research · 2026Review
- Probiogenomic analysis of functional potential and safety ofMicrobiology spectrum · 2026Article
- Survival and Behavior of Potential Emerging Foodborne PathogenFood science & nutrition · 2026Article
- Exploring tumour-microbe interactions: in vitro and in vivo modelling of Streptococcus bovis-induced colorectal carcinogenesis.Molecular biology reports · 2025Review
- The Interplay Between the Gut Microbiota and Colorectal Cancer: A Review of the Literature.Microorganisms · 2025Review
- Small Biological Fighters Against Cancer: Viruses, Bacteria, Archaea, Fungi, Protozoa, and Microalgae.Biomedicines · 2025Review
- Dysbiosis and colorectal cancer: conducive factors, biological and molecular role, and therapeutic prospectives.Exploration of targeted anti-tumor therapy · 2025Review
- Comprehensive fecal metagenomic and metabolomic analysis reveals the role of gut microbiota and metabolites in detecting brain metastasis of small cell lung cancer.Frontiers in microbiology · 2025Article
- Gut commensal Alistipes as a potential pathogenic factor in colorectal cancer.Discover oncology · 2024Article
- Microbiota, natural products, and human health: exploring interactions for therapeutic insights.Frontiers in cellular and infection microbiology · 2024Review
- Factors underlying the association betweenGut microbiome (Cambridge, England) · 2024Review
- Ecotoxicological Study of Tannic Acid on Soil and Water Non-Target Indicators and Its Impact on Fluvial and Edaphic Communities.Plants (Basel, Switzerland) · 2023Article
- Association of theOpen forum infectious diseases · 2023Article
- Microbial-Transferred Metabolites of Black Tea Theaflavins by Human Gut Microbiota and Their Impact on Antioxidant Capacity.Molecules (Basel, Switzerland) · 2023Article
- Beneficial Effects ofMicroorganisms · 2023Article
- Gut microbiota and its metabolites in non-small cell lung cancer and brain metastasis: from alteration to potential microbial markers and drug targets.Frontiers in cellular and infection microbiology · 2023Article
- Comprehensive analysis of the metabolic and genomic features of tannin transforming Lactiplantibacillus plantarum strains.Scientific reports · 2022Article
- Gut microbiota, inflammatory bowel disease and colorectal cancer.World journal of gastroenterology · 2022Review
- Microbiota and cancer: current understanding and mechanistic implications.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022Review
- A structurally unique Fusobacterium nucleatum tannase provides detoxicant activity against gallotannins and pathogen resistance.Microbial biotechnology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The tannase-producing Gram-positive bacterial species Streptococcus gallolyticus subsp. gallolyticus (Sgg) is an opportunistic pathogen of the human gut and strongly associated with colorectal cancer (CRC). A unique feature of Sgg is its ability to degrade tannic acids (TA). TA constitute an important part of the human diet with known anti-tumorigenic properties. Here, we examined whether Sgg is able to protect tumor cells from the toxic effect of TA and thus drive tumorigenesis indirectly. Human CRC cell lines (n = 8) were treated with increasing concentrations of TA. We confirmed the cytotoxic activity of TA in a dose-dependent manner. In virtually all cell lines, viability decreased significantly (>60% inhibition). Moreover, pyrogallol, the degradation product of TA, had no effect on the tested cell lines. This suggests a specific effect of TA. Cytotoxicity was due to necrosis and induction of senescence in residual cells. Finally, when TA was degraded by Sgg, the cytotoxic effect could be abolished. Tumor cells even responded with boosted cell proliferation, highlighting the impact of Sgg on CRC progression. We here provide another piece of evidence for the active interplay between Sgg and cancer preventive components. These data will help to move forward in designing concepts for therapeutic and eventually also prophylactic approaches to combat gastrointestinal malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.